• Govconnect

NHS Long Term Plan 2020 - Partner Profile - Fibricheck

Updated: Mar 5, 2020

Who are Fibricheck?

FibriCheck is trailblazing preventive heart care and is recognized around the world as being the first CE-marked and FDA-approved application capable of timely detection of heart rhythm disorders, including atrial fibrillation (AF), using a regular smartphone or smartwatch. FibriCheck produces accurate real-time heart rhythm analysis thanks to its clinically validated PPG technology, turning heart rhythm monitoring into an at-home solution that can be used by anyone at any time, without costly hardware. FibriCheck is recommended by leading cardiologists and GPs and used in a variety of settings.

As solution born out of a clinical unit, we draw on our extensive medical and technical know-how to deliver evidence-informed, diagnostic grade functionality typically reserved for ECG hardware devices. Over the years we have refined FibriCheck based on patient-reported feedback and outcomes, additionally aligning with HCP needs as it relates to guidelines and standards. Today our clinical team continues to lead and contributed to a diverse range of research papers and studies on a variety of AF issues such as early identification in primary and secondary settings, stroke prevention, in and outpatient care strategy, clinical outcomes post intervention and medication management, post-surgical monitoring.

How has FibriCheck improved outcomes for the NHS and patients?

FibriCheck offers more efficient care and follow-up of (a)symptomatic patients, along with an effective (pre)screening of high-risk patients. By offering the possibility to do self-monitoring at home without the hassles of hardware, FibriCheck provides peace of mind, improves QoL and eliminates unnecessary doctor visits.

Our collaboration with Helicon Health and the NHS empowers CCGs, HCPs and patients by harnessing the power of data for the early detection of AF and prevention of stroke. Aligning with AF NICE Guidelines, FibriCheck is increasing access for patients, regardless of geography by bringing care closer to home and improving outcomes – saving time and resources. Our data analytics work in this capacity to support the business cases needed by system funders to evaluate cost-saving digital solutions.

Our impact on the frontline of care is backed by our successful completion of the ORCHA Review process, which is today the most advanced review mechanism for health and care apps available anywhere. Achievement of this milestone has helped further our validation with the NHS App store, giving confidence to patients when choosing clinically approved applications to support their health. While we empower patients to be in the driver’s seat, our medical review and personalised reports support their navigation – offering peace of mind and intelligently filling waiting room with those that need it the most.

What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?

- The world’s first CE-marked and FDA-approved hardware-independent application capable of real-time detection of heart rhythm disorders, including atrial fibrillation, using only a smartphone or smartwatch

- Clinically validated application with proven equivalence to single-lead ECG devices

- Organisation of record population screening – 65,000 people onboarded in one week, with 3 more countrywide/ large scale initiatives slated for 2020

How many organisations/clients currently utilize the service/solution across the UK?

In addition to our work with Helicon, CCGs and ORCHA, our partnership with Fitbit has helped to bring the power of FibriCheck to wearables - expanding access for over 20,000 UK residents, and counting.

Is there anything you would like to make delegates aware of ahead of the NHS Long Term Plan 2020 conference on 29th April?

Currently, we are extending the functionality on commercial wearable devices for overnight continuous heart monitoring, thereby greatly increasing the chance of detection for intermittent AF episodes, as commonly occurs in early stages. This capability, enabled by machine learning algorithms, is key to its preventive power. This data contributes to longitudinal information and provides valuable insights into patients, for doctors, system funders, research and medicine.

This advancement, in complement to our acceptance into the 2020 Cohort of the NHS Innovation Accelerator programme (NIA), will help spread and increase access for citizens across the UK.

What do you feel are the key points delegates need to digest when considering a partnership with FibriCheck?

- Seamless integration into care pathways

- Timely detection of cardiac arrhythmias through a smartphone or smartwatch, additional hardware not required

- Proven clinical equivalence to single-lead ECG devices

- FDA-cleared in the US, CE-marked in Europe

- A wide number of use cases, ranging from +100K digital pre-screening projects to follow-up of specific patient groups. Cost-efficiency demonstrated and cost-saving for specific target groups

FibriCheck offers more than just a digital solution. Our team of medical experts, researchers, educators and campaign specialists bring a holistic approach to every project and awareness initiative we support. So, whether it’s onboarding and educating HCPs, collecting and analysing outcomes data, or creating dynamic content for patients and care providers, we at FibriCheck understand it takes more than just tools to transform, you need to put people at the heart of the matter.

If you would like to learn more about FibriCheck please contact: info@fibricheck.com or please visit http://www.fibricheck.com/

3,863 views0 comments

Recent Posts

See All

Who are iRhythm? iRhythm Technologies is a digital healthcare company which is redefining the way cardiac arrhythmias are clinically diagnosed with its Zio service. Zio by iRhythm is a NICE-recommende